Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies, Obesity Weight Loss, Schizophrenia, Hospital, Psychiatric |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 11/8/2014 |
| Start Date: | February 2008 |
| End Date: | June 2012 |
| Contact: | Saurabh Kaushik, MD |
| Email: | maisskk@omh.state.ny.us |
| Phone: | 646-672-6352 |
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study
This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable
antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in
patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent,
will lead to improved cognition, increased wakefulness, and decreased weight in patients
with schizophrenia who are on stable antipsychotic regimens
antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in
patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent,
will lead to improved cognition, increased wakefulness, and decreased weight in patients
with schizophrenia who are on stable antipsychotic regimens
Inclusion Criteria:
- DSM-IV diagnosis of schizophrenia (all subtypes), illness duration greater than three
years
- Auditory and visual acuity adequate to complete cognitive tests
- Stable dose of antipsychotics for at least 2 weeks prior to entry
- Good physical health determined by complete physical examination, laboratory tests,
and EKG
- Capacity and willingness to give written informed consent.
Exclusion Criteria:
- Inability to read or speak English
- Documented disease of the central nervous system
- History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g.
mental retardation)
- Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal,
pulmonary or hematologic conditions;
- HIV positive
- Patients on antidepressants, including MAO inhibitors
- Uncontrolled hypertension
- Pregnancy
- Patients with a current diagnosis of substance dependence
- Significant history of violence
- History of an eating disorder
- Ready for discharge within the following 8 weeks.
We found this trial at
1
site
Click here to add this to my saved trials
